Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Algernon Pharmaceuticalsinc (AGN.CN)

Algernon Pharmaceuticalsinc (AGN.CN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 12,562
  • Shares Outstanding, K 167,487
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,538 K
  • 60-Month Beta 0.04
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.29
Trade AGN.CN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.08
  • Most Recent Earnings -0.01 on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.075 +6.67%
on 10/20/21
0.100 -20.00%
on 09/24/21
-0.010 (-11.11%)
since 09/21/21
3-Month
0.075 +6.67%
on 10/20/21
0.130 -38.46%
on 08/12/21
-0.005 (-5.88%)
since 07/21/21
52-Week
0.075 +6.67%
on 10/20/21
0.540 -85.19%
on 12/15/20
-0.200 (-71.43%)
since 10/21/20

Most Recent Stories

More News
The Power Play by The Market Herald Announces Interviews with Algernon Pharmaceuticals, NextechAR, UCore Rare Metals, Falcon Gold, and Durango Resources on Latest Company News

VANCOUVER, BC / ACCESSWIRE / October 15, 2021 / The Market Herald, the leading source of authoritative breaking stock market news for self-directed investors spoke with Algernon Pharmaceuticals, UCore...

AGN.CN : 0.080 (+6.67%)
AGNPF : 0.0648 (+6.23%)
FG.VN : 0.105 (-4.55%)
FGLDF : 0.0935 (+3.66%)
NTAR.CN : 1.870 (-1.58%)
NEXCF : 1.5272 (-1.28%)
DGO.VN : 0.060 (unch)
UCU.VN : 0.940 (-2.08%)
UURAF : 0.7648 (-0.84%)
Algernon Pharmaceuticals Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Chronic Cough Phase 2 Study

VANCOUVER, British Columbia, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or...

AGN.CN : 0.080 (+6.67%)
AGNPF : 0.0648 (+6.23%)
Hagens Berman: Law Firm Investigating Permanent Injuries and Disfigurement from Botched CoolSculpting Procedures

Consumer-rights and personal injury law firm Hagens Berman has launched a nationwide investigation into CoolSculpting regarding the risk of permanent disfigurement and serious harm to patients’ bodies...

AGN : 193.02 (+0.02%)
AGN.CN : 0.080 (+6.67%)
Ifenprodil: The Drug That Tamed the World’s Most Lethal Flu has its Debut for COVID

Before COVID-19 very few people across the globe knew what re-purposing a drug meant. Hydroxychloroquine, ...

GILD : 66.99 (+0.19%)
AGN.CN : 0.080 (+6.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 0.088
2nd Resistance Point 0.087
1st Resistance Point 0.083
Last Price 0.080
1st Support Level 0.078
2nd Support Level 0.077
3rd Support Level 0.073

See More

52-Week High 0.540
Fibonacci 61.8% 0.362
Fibonacci 50% 0.308
Fibonacci 38.2% 0.253
Last Price 0.080
52-Week Low 0.075

See More

Business Summary

Algernon Pharmaceuticals Inc is a clinical stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough, and COVID-19. The company operates in two reportable segments being the development of repurposed therapeutic drugs in Canada and the facilitation...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar